Acute myocardial infarction Circulatory System Infarction
Conditions
Interventions
Percutaneous Coronary Intervention using either the Bx VELOCITYTM stent coated with rapamycin (Cypher) or the TaxusTM stent coated with Paclitaxel.
Sponsors
Isala klinieken (The Netherlands)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with acute myocardial infarction, presenting within six hours after symptom-onset, or those presenting between six and 24 hours if persisting chest pain associated with clinical evidence of on-going ischaemia occurs 2. Culprit lesion in a native coronary artery, suitable for stenting 3. Lesion length of less than 30 mm, located in a vessel of more than 2.5 mm 4. Able to deliver the stent to target lesion (absence of diffuse disease or excessive proximal vessel tortuosity) 5. Absence of no-reflow or extensive thrombus throughout vessel
Exclusion criteria
Exclusion criteria: 1. Women of child-bearing potential 2. Severe hepatic or renal disease 3. Previous participation in the study 4. Life expectancy of less than one year 5. Factors making follow-up difficult 6. Acute myocardial infarction pre-treated with thrombolysis 7. Unprotected left main disease or single remaining vessel 8. Target lesion in a bifurcation with a large side-branch 9. Known sensitivity to aspirin or coumarin 10. Unable to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major adverse cardiac clinical events (death, re-infarction, target vessel revascularisation) at one, nine and 12 months after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Late lumen loss at nine months follow-up by quantitative coronary angiography | — |
Countries
Netherlands
Outcome results
None listed